Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Stewart

Urogynecology and Reconstructive Pelvic Surgery Green Bay, WI Doctor of Osteopathy

NPI 1922366061 CMS profile 2787486

2845 Greenbrier Rd, Green Bay, WI 54311

Open in the dashboard

General payments

$4,818

63 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Stewart of Green Bay, WI is reported in the CMS Open Payments database as having received $4,818 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $254 5
2024 General $891 7
2023 General $2,583 20
2022 General $104 1
2021 General $19 1
2020 General $226 7
2019 General $741 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Stewart
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to James Stewart were reported at $254. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year James Stewart Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $741 $358 $132–$1,270 $163
2020 $226 $198 $86–$642 $114
2021 $19 $361 $118–$1,182 $132
2022 $104 $410 $128–$1,175 $149
2023 $2,583 $434 $152–$1,344 $160
2024 $891 $494 $193–$1,331 $164
2025 $254 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $1,426 12 payments
  2. Intuitive Surgical, Inc. $1,209 6 payments
  3. Coloplast Corp $550 5 payments
  4. Medtronic USA, Inc. $431 16 payments
  5. Bluewind Medical $372 2 payments
  6. Boston Scientific Corporation $286 7 payments
  7. AbbVie, Inc. $194 4 payments
  8. Applied Medical Resources Corporation $104 1 payment
  9. Baxter Healthcare $85 1 payment
  10. Hologic, LLC $45 2 payments
  11. Other $117 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,163 57 payments
  2. Travel and Lodging $1,509 5 payments
  3. Education $147 1 payment
Products named General payments · program years 2019–2025
  1. Axonics $1,426 12 payments
  2. Da Vinci Surgical System $1,209 6 payments
  3. INTERSTIM $431 16 payments
  4. REVI $372 2 payments
  5. Altis $302 3 payments
  6. Bulkamid $198 3 payments
  7. SUPRIS $147 1 payment
  8. Orilissa $141 2 payments
  9. GelPOINT V-Path $104 1 payment
  10. Titan $101 1 payment
  11. Other $676 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

337

Median for Obstetrics & Gynecology: 65

Drug cost

$102,358

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

46.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 69 $55,828
Myrbetriq Mirabegron Brand 41 $24,444
Estradiol Generic 132 $11,411
Premarin Estrogens, Conjugated Brand 15 $6,372
Fosfomycin Tromethamine Generic 24 $2,311
Yuvafem Estradiol Brand 15 $1,296
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 17 $302
Solifenacin Succinate Generic 11 $240
Cephalexin Generic 13 $155

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$41,811

Medicare's payments for the services billed

Medicare patients

109

Average age 73

Services billed

457

109 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 58%
Depression 35%
Chronic kidney disease 26%
Diabetes 24%
Osteoporosis 24%
Ischemic heart disease 21%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record